Notable Gender, Racial Disparities Exist Among U.S. Clinical Investigators, According to the Tufts Center for the Study of Drug Development
November 13, 2007 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - November 13, 2007) - Although the overwhelming majority of physicians
in the United States have high interest in participating in clinical
research studies, the actual...
Despite More Cancer Drugs in R&D, Overall U.S. Approval Rate Is Eight Percent, According to the Tufts Center for the Study of Drug Development
September 05, 2007 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - September 5, 2007) - Although the number of new cancer drugs entering
clinical development more than doubled between the early 1990s and
mid-2000s, only eight percent of...
Follow-on Drugs Are Key to World Health Organization, According to the Tufts Center for the Study of Drug Development
July 10, 2007 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - July 10, 2007) - Follow-on drugs play a central role in World
Health Organization (WHO) drug policy, suggesting that initiatives which
impede follow-on drug research and...
Results Mixed on Postmarketing Studies of New Drugs, According to the Tufts Center for the Study of Drug Development
May 15, 2007 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA -- (MARKET WIRE) -- May 15, 2007 -- While drug developers over the past six years
have stepped up the number of postmarketing studies they conduct on newly
approved medicines, sponsors feel...
Big Pharma-Biotech Partnering Holds Promise for Improving R&D Productivity, According to Industry Panel Convened by the Tufts Center for the Study of Drug Development
March 26, 2007 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA -- (MARKET WIRE) -- March 26, 2007 -- Challenged to maintain revenue growth over the
next five years, large pharmaceutical companies increasingly will partner
with biotech firms to improve...
Pediatric Study Costs Rose Substantially From 2000 as Complexity Grew, According to Tufts Center for the Study of Drug Development
March 13, 2007 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA -- (MARKET WIRE) -- March 13, 2007 -- The average cost to complete pediatric research
on already marketed prescription drugs, in response to a request from the
U.S. Food and Drug...
European Union Meeting Performance Goals for New Drug Review, but Lags Behind U.S. in New Drug Availability, According to Tufts Center for the Study of Drug Development
January 16, 2007 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA -- (MARKET WIRE) -- January 16, 2007 -- Review times for new drugs in the European Union
have met mandated performance goals, but many medicines are available in the United
States prior to...
Despite Development Challenges, Drug Developers Have Reason to Be Optimistic, According to Tufts Center for the Study of Drug Development
January 03, 2007 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA -- (MARKET WIRE) -- January 3, 2007 -- Despite a growing list of development challenges
-- including rising R&D costs, increasing regulatory stringency, and
mounting public hostility...
Average Cost to Develop a New Biotechnology Product Is $1.2 Billion, According to the Tufts Center for the Study of Drug Development
November 09, 2006 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA -- (MARKET WIRE) -- November 9, 2006 -- The Tufts
Center for the Study of Drug Development today announced it has
developed the first comprehensive estimate of the average cost...